DK177585A - Pyridazinoner - Google Patents

Pyridazinoner Download PDF

Info

Publication number
DK177585A
DK177585A DK177585A DK177585A DK177585A DK 177585 A DK177585 A DK 177585A DK 177585 A DK177585 A DK 177585A DK 177585 A DK177585 A DK 177585A DK 177585 A DK177585 A DK 177585A
Authority
DK
Denmark
Prior art keywords
pyridazinones
alkoxy
denotes
bronchospasmolytic
polyfluoro
Prior art date
Application number
DK177585A
Other languages
English (en)
Other versions
DK159431C (da
DK159431B (da
DK177585D0 (da
Inventor
Hermann Amschler
Klaus Eistetter
Manfrid Eltze
Dieter Flockerzi
Ulrich Kilian
Norbert Kolassa
Karl Sanders
Wolf-Ruediger Ulrich
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of DK177585D0 publication Critical patent/DK177585D0/da
Publication of DK177585A publication Critical patent/DK177585A/da
Publication of DK159431B publication Critical patent/DK159431B/da
Application granted granted Critical
Publication of DK159431C publication Critical patent/DK159431C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK177585A 1984-05-10 1985-04-19 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler DK159431C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229784 1984-05-10
CH229784 1984-05-10

Publications (4)

Publication Number Publication Date
DK177585D0 DK177585D0 (da) 1985-04-19
DK177585A true DK177585A (da) 1985-11-11
DK159431B DK159431B (da) 1990-10-15
DK159431C DK159431C (da) 1991-03-18

Family

ID=4230485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK177585A DK159431C (da) 1984-05-10 1985-04-19 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler

Country Status (15)

Country Link
US (1) US4665074A (da)
EP (1) EP0163965B1 (da)
JP (1) JPH062750B2 (da)
AT (1) ATE47844T1 (da)
AU (1) AU578947B2 (da)
CA (1) CA1245651A (da)
DE (1) DE3574137D1 (da)
DK (1) DK159431C (da)
ES (1) ES8607950A1 (da)
GR (1) GR851039B (da)
IE (1) IE58033B1 (da)
IL (1) IL75070A (da)
NZ (1) NZ211995A (da)
PT (1) PT80426B (da)
ZA (1) ZA853504B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2075202T3 (es) * 1989-04-17 1995-10-01 Byk Gulden Lomberg Chem Fab Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
DE59109027D1 (en) * 1990-10-16 1998-08-13 Byk Gulden Lomberg Chem Fab Arylpyridazinone
EP0581805A1 (de) * 1991-04-26 1994-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
JPH06508842A (ja) 1991-07-05 1994-10-06 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 置換ピリダジンの皮膚病に対する使用
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
JP2002502403A (ja) 1997-06-03 2002-01-22 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ベンゾナフチリジン
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
US20040180900A1 (en) 2001-05-23 2004-09-16 Masaharu Takigawa Therapeutic composition for repairing chondropathy
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7417055B2 (en) * 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP2266994B1 (en) * 2004-08-02 2013-04-03 University Of Virginia Patent Foundation 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PE20110219A1 (es) * 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435244A1 (de) * 1974-07-22 1976-02-05 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
DE2445681A1 (de) * 1974-09-25 1976-04-15 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
JPS6037101B2 (ja) * 1977-03-09 1985-08-24 三共株式会社 フエニルピリダジノン誘導体の製法
DE2757923A1 (de) * 1977-12-24 1979-06-28 Hoechst Ag Verfahren zur herstellung von 3-pyridazonen
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
GR82072B (da) * 1983-05-11 1984-12-13 Byk Gulden Lomberg Chem Fab
IT1173591B (it) * 1983-05-11 1987-06-24 Byk Gulden Lomberg Chem Fab Piridazioni,loro preparazione e impiego,farmaci contenenti piridazioni

Also Published As

Publication number Publication date
IE851146L (en) 1985-11-10
CA1245651A (en) 1988-11-29
NZ211995A (en) 1987-11-27
JPS60246375A (ja) 1985-12-06
IL75070A0 (en) 1985-09-29
DK159431C (da) 1991-03-18
IE58033B1 (en) 1993-06-16
EP0163965B1 (de) 1989-11-08
IL75070A (en) 1988-11-15
GR851039B (da) 1985-05-28
ZA853504B (en) 1985-12-24
DK159431B (da) 1990-10-15
JPH062750B2 (ja) 1994-01-12
DK177585D0 (da) 1985-04-19
ES8607950A1 (es) 1986-06-16
EP0163965A2 (de) 1985-12-11
US4665074A (en) 1987-05-12
EP0163965A3 (en) 1987-06-24
DE3574137D1 (en) 1989-12-14
PT80426A (de) 1985-06-01
AU4177585A (en) 1985-11-14
ATE47844T1 (de) 1989-11-15
ES542979A0 (es) 1986-06-16
PT80426B (de) 1987-04-16
AU578947B2 (en) 1988-11-10

Similar Documents

Publication Publication Date Title
DK177585A (da) Pyridazinoner
ES8702371A1 (es) Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
DK24984D0 (da) 6-(acylaminoaryl)-3(2h)-pyridazinonderivater og deres anvendelse som laegemidler
ES8102561A1 (es) Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
ES8403472A1 (es) Procedimiento para la obtencion de un medio para combatir las pestes a base de como minimo de aminocetal.
AU560607B2 (en) Pyridazinones their preparation and use and medicaments containing pyridazinones
ES8203855A1 (es) Un procedimiento para la preparacion de derivados de imida- lol.
IE780279L (en) Imidazole derivatives
GB1262267A (en) Substituted 2-amino-3-imino-3,5-dihydrophenazines
ES8106156A1 (es) Un procedimiento para la preparacion de derivados de oxadia-zolotriazona
AU573062B2 (en) Dihydrodithiazine derivatives
ES8103047A1 (es) Procedimiento de preparacion de derivados aminoisoquinolinosasi como de sus sales de adicion acidas, farmaceuticamente aceptables y de sus derivados amonicos cuaternarios
NO932002L (no) Nye tiosemikarbazonsyreestere
ES517874A0 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.
ES8500619A1 (es) Procedimiento de preparacion de derivados de eburnano-oxima racemicos u opticamente activos.
SU1266156A1 (ru) 7-морфолинокумарины в качестве красителей для лазерной техники
MY102050A (en) Imidazole anologs of mevalonolactone and derivatives thereof
ATE56445T1 (de) Pharmacologisch aktive propionylanilide.

Legal Events

Date Code Title Description
PBP Patent lapsed